A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937

Overactive Bladder

COMPLETED PHASE4

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

NCT00798434

Urinary Bladder, Overactive

COMPLETED PHASE4

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450

Parkinson's Disease Overactive Bladder

COMPLETED NA

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

NCT00928070

Overactive Bladder

COMPLETED PHASE4

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

NCT02385500

Urinary Bladder, Overactive Parkinson Disease

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized placebo controlled, blinded four way cross over trial of the effect of medications used to treat overactive bladder on the cognition of older men and women with mild cognitive impairment. Each treatment phase is a week, with a weeks washout period before starting the next treatment. Cognitive testing is by way of a validated computer assisted battery of tests

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fesoterodine 4mg daily

fesoterodine 4mg oral

Group Type EXPERIMENTAL

fesoterodine 4mg

Intervention Type DRUG

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Oxybutynin

Intervention Type DRUG

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

placebo

Intervention Type DRUG

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

fesoterodine 8mg

Intervention Type DRUG

2, 4mg fesoterodine capsules taken together in the morning

Fesoterodine 8mg

Fesoterodine 8mg in form of 2, 4mg tablets

Group Type EXPERIMENTAL

fesoterodine 4mg

Intervention Type DRUG

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Oxybutynin

Intervention Type DRUG

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

placebo

Intervention Type DRUG

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

fesoterodine 8mg

Intervention Type DRUG

2, 4mg fesoterodine capsules taken together in the morning

oxybutynin

oxybutynin immediate release, encapsulated 2, 5mg capsules daily

Group Type ACTIVE_COMPARATOR

fesoterodine 4mg

Intervention Type DRUG

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Oxybutynin

Intervention Type DRUG

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

placebo

Intervention Type DRUG

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

fesoterodine 8mg

Intervention Type DRUG

2, 4mg fesoterodine capsules taken together in the morning

placebo capsule

placebo capsule, 2 per day

Group Type PLACEBO_COMPARATOR

fesoterodine 4mg

Intervention Type DRUG

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Oxybutynin

Intervention Type DRUG

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

placebo

Intervention Type DRUG

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

fesoterodine 8mg

Intervention Type DRUG

2, 4mg fesoterodine capsules taken together in the morning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fesoterodine 4mg

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Intervention Type DRUG

Oxybutynin

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

Intervention Type DRUG

placebo

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

Intervention Type DRUG

fesoterodine 8mg

2, 4mg fesoterodine capsules taken together in the morning

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Toviaz ditropan placebo capsule Toviaz 8mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject is either male or female and ≥ 75 years of age.
2. The subject has OAB as determined by ICS criteria
3. The subject has mild cognitive impairment as determined by NIA criteria
4. The subject is competent to give informed consent and perform the tasks associated with the study
5. The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive.
6. Written informed consent has been obtained.
7. The subject is available to complete the study.
8. At training visits (visit 2): the subject has performed at or above the minimum level on at least one occasion for each individual task measure in cognitive function test training.

Exclusion Criteria

1. The subject does not have OAB.
2. The subject has either dementia or moderate to severe cognitive impairment at screening.
3. The subject has probable clinical depression as determined by Geriatric Depression Scale (GDS) short form \>5 at screening.
4. Subjects taking any cognitive enhancers (cholinesterase inhibitors or memantine).
5. The subject has a history of allergy to the study drug(s), to any component of the dosage form or any other allergy, which, in the opinion of the Investigator, contraindicates their participation.
6. The subject has any clinically significant abnormal heart rate or blood pressure measurements, at the screening visit, which, in the opinion of the Investigator, prevent safe participation in the study. (dBP\< 60mmHg or \> 90mmHg, sBP \< 95mmHg or \> 160mmHg or HR \< 40bpm or \> 100bpm).
7. Subjects with known history of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony) or severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow interior chamber or subjects deemed to be at risk for these conditions.
8. Subjects undergoing haemodialysis or who have severe renal impairment.
9. Subjects with severe hepatic impairment, defined as Child-Pugh grade IV.
10. Subjects taking potent CYP 3A4 inhibitors which would, under normal circumstances, require adjustment of the dose of the test drugs.
11. Subject has taken prescribed medication within 14 days prior to the first study day or over-the-counter medicine (including vitamins and herbal remedies) within 48 hours prior to the first study day, which in the opinion of the Investigator, will interfere with the study procedures or compromise safety.
12. Subject has an average weekly alcohol intake of greater than 21 units (male) or 14 units (female) within the 90 days prior to the study. 1 unit is 270cc of beer, 40cc of spirits or 125cc of wine.
13. History of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per day within the 90 days prior to the study.
14. Subject has participated in any clinical study within the last 90 days.
15. Any clinically significant abnormality following Investigator review of the pre study physical examination.
16. Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.
17. Any subjects who, in the opinion of the investigator, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol.

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No